Equillium, Inc. 8-K

What Happened

• On March 11, 2026 (8‑K filed March 13, 2026), Equillium, Inc. announced it entered into a Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. for a private placement expected to close on or about March 13, 2026.
• The Company agreed to sell 1,179,508 shares of common stock at $1.854 per share and a pre‑funded warrant to purchase up to 17,698,593 shares at $1.8539 per warrant share, for gross proceeds of approximately $35.0 million. The pre‑funded warrant has an exercise price of $0.0001 per share, is exercisable at any time (including cashless/net exercise), and does not expire until fully exercised; exercise is subject to a beneficial ownership limitation (not to exceed 19.99%).

Key Details

• Investor: RA Capital Healthcare Fund, L.P.
• Shares to be issued: 1,179,508 common shares at $1.854 each.
• Pre‑funded warrants: to purchase up to 17,698,593 shares at $1.8539 each; exercise price $0.0001 per share.
• Gross proceeds to Equillium: approximately $35.0 million.
• Registration Rights: Equillium agreed to file a resale registration statement within 30 days after closing (subject to limited delays); cash penalties apply for registration failures.

Why It Matters

• Financing: The transaction provides Equillium with immediate capital (~$35M) to support operations or development programs without going public with an offering.
• Potential dilution: If the pre‑funded warrants are exercised, outstanding shares will increase; however, the pre‑funded structure and the 19.99% ownership cap limit immediate large shifts in control.
• Liquidity for investor: Registration rights mean the issued shares and warrant shares are intended to become registrable for resale, which could increase the tradability of those shares once the registration statement is effective.
• No other financial results or executive changes were reported in this filing; investors should monitor subsequent disclosures for use of proceeds and any impact on financial guidance.